EFA PATIENTS’ DIGITAL PRIZE 2023
Terms of Reference for Jury Members
EFA Patients' Digital Prize

Terms of reference for jury members

INTRODUCTION

The European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) is an independent non-profit organisation with its central office located in Brussels, Belgium. EFA connects 45 allergy, asthma, and chronic obstructive pulmonary disease (COPD) patients’ associations in 26 countries.

In the first half of 2023, EFA will be granting a Patient’s Digital Prize to reward patient-centred digital health initiatives that centre patients through their design, accessibility, and efficacy.

BACKGROUND

In 2020 EFA launched the Digital Information Technology (DIG_IT) Project, which aimed at bringing asthma and COPD patients to the heart of the digital solutions they use. The project included a patient survey conducted in five different European countries and involving 970 patients. The results have been published in DIG_IT Report: Asthma and COPD patients’ digital journey in Europe (2021).

The EFA’s DIG_IT Project, survey and survey report have been funded with unrestricted grants from EFA’s Sustainable Corporate Partners Astra Zeneca, Chiesi, MSD, OM Pharma and Roche. The EFA’s DIG_IT Prize is being made possible thanks to unrestricted grants from EFA’s Sustainable Corporate Partners Chiesi and Roche.

SCOPE

The prize will be granted to digital health technologies. The prize aims to mark the recognition of a creator and/or a developer of a technology or system as a good solution for asthma and COPD patient-centred digital health care.
The **EFA Patients’ Digital Prize** will acknowledge digital technologies that fit in one of three disease-focused categories:

- Prize for best digital technology covering asthma.
- Prize for best digital technology covering COPD.
- Prize for best digital technology covering both asthma & COPD.

To choose the winners of each category, a jury panel of eight individuals will be selected by EFA Office by March 2023 that is composed of:

- 1 asthma patients’ representative from EFA Members.
- 1 COPD patients’ representative from EFA Members.
- 1 young asthma patient from the European Allergy & Asthma Youth Parliament.
- 1 healthcare professional from the respiratory sector.
- 1 digital health industry expert.
- 1 payer representative.
- 1 European/EU Digital Health Authority representative.
- 1 representative from the EFA Sustainable Corporate Partners (pharma) that supports the EFA DIG_IT project with unrestricted grants.

**TIMELINE OF THE COMPETITION**

The **EFA Patients’ Digital Prize** has the following timeline:

- Call for submissions: Wednesday 1 February 2023 – Monday 27 March 2023 (eight weeks)
- Selection of the Jury: March 27, 2023
- Evaluation period: March 28, 2023 – April 2, 2023
- Announcement of finalists: April 10, 2023
- Prize ceremony: 27-28 April 2023 in Ghent, Belgium

**RESPONSIBILITY OF JURY MEMBERS**

Members selected to play a role on the jury will have the duty to fulfil the following responsibilities during the selection process:
▪ Read and follow the terms of reference, evaluation criteria and all other guidelines applicable that correspond to the **EFA Patients’ Digital Prize**.

▪ Upon reception of applications, members of the jury must promptly and fully disclose any potential conflict of interest in relation to any of the applicants/submissions, and refrain from taking part in the assessment of that category to which the submission has been made. Jury members must notify EFA Office in writing of the potential conflict of interest as soon as possible.

▪ Attend the jury meeting(s) moderated by EFA held online.

▪ Use their knowledge and expertise to evaluate each submission.

▪ Follow the principles of fairness, transparency, and independence throughout the process of evaluation of submissions.

▪ Evaluate submissions without influence by either personal or third-party interests, and without involvement of any personal bias related to their main area of work and expertise.

▪ Treat as strictly confidential, all content-related and administrative details related to the submissions, applicants, process of selection.

Throughout the evaluation period, members of the jury will conduct their evaluation(s) according to a flexible timeline but will be required to dedicate up to one working day throughout the two weeks allocated for the evaluation.

**METHODS OF EVALUATION**

The assessment of the submissions will be done by all the jury members, on the basis of their responsibilities as laid down in Article 5 of this document, according to the prize evaluation grid, and taking into account the evaluation criteria set out for the purpose of the **EFA Patients’ Digital Prize**.

There are six main criteria on which jury members will base their evaluation: accessibility, partnership with healthcare professionals, convenience, support, and security, prevention, and equity of the technology submitted.

Jury members will grade each submission individually based on the prize evaluation grid. For each of the six criteria, jury members will award a maximum of 5 points, amounting to a maximum total of 70 points.
Once all submissions have been scored by each jury member, members of the jury will participate in at least one assessment coordination meeting for the evaluation of the submissions and selection of the prize winners for each category.

**COMPENSATION & REIMBURSEMENT**

Members of the jury are expected to fulfil their duties on a volunteer basis, and no compensation is envisaged. In case of travel/expenditure costs for the purpose of fulfilling the duties within the scope of the EFA Patients’ Digital Prize, EFA will cover the expenses in accordance with EFA’s Expenses and Reimbursement Policy.

**DURATION & TERMINATION**

Jury members are appointed for the full duration of the 2023 prize evaluation process, and they must fulfil and comply with their duties for the entire period of their appointment.

Under exceptional conditions, and in the event of unforeseen circumstances that prevent jury members from fulfilling their duties in full, jury members can notify EFA Office of the termination of their appointment.

Should the EFA Secretariat Office be aware of a potential conflict of interests that has not been notified by the jury members, EFA has the discretion to immediately stop the collaboration with the jury member in question.

**COMMUNICATION & SOCIAL MEDIA**

By taking part in the evaluation/selection of the EFA Patients’ Digital Prize, each jury member consents to receiving electronic communications from EFA in relation to any issues related to the prize. Examples include, but are not limited to, the selection process, request of additional information, and information about the prize ceremony.

Jury members will be requested either to provide and/or partake in various promotional materials during the prize process, including supply of a short bio and photo to be included on the prize website. Throughout and after the competition, jury members may
be requested to participate in short promotional videos shared on the relevant social media channels. By taking part in the prize, jury members consent to having this information made public, unless explicitly requested otherwise by contacting in writing the EFA Office.

Disclaimer

The EFA Patients’ Digital Prize acts purely as a recognition and acknowledgement of digital developments in health which put asthma and COPD patients’ needs at the heart of digital solutions. The EFA Patients’ Digital Prize does not certify in any form whatsoever the use of an end product that arises from the submission(s). The prize applies only to the digital technology as submitted by the applicant, and not to any subsequent developments of that digital technology. As such, EFA does not take any responsibility for, nor does it recognise any of the further developments of, the submission beyond what has been submitted for the consideration of the prize.

Privacy Policy

By participating in the EFA Patients’ Digital Prize, jury members accept EFA’s Privacy Policy.

Intellectual Property Rights

EFA holds all the intellectual property rights related to the EFA Patients’ Digital Prize, including its concept and organisation. Any intellectual property rights based in the submissions to the prize belong to the respective applicants.

Limitations of Liability

In the absence of negligence, bad faith, or wilful misconduct, EFA shall not be liable to any applicant or jury member, or any other person, including any party claiming by, through or on behalf of the applicants or jury members, for any losses, liabilities, damages, costs, or expenses arising out of an error in data or other information provided to them.

EFA does not take any responsibility for any losses, liabilities, damages, costs, or expenses arising out of the use of the digital health technology and/or systems submitted for consideration within the EFA Patients’ Digital Prize, nor any subsequent developments of the submissions to the prize.

Contact Details

European Federation of Allergy and Airways Diseases Patients Associations

35 Rue du Congrès, 1000 Brussels, Belgium
Projects@efanet.org
+32(0)2 227 27 12
EU Transparency Register Identification Number: 28473847513-94

Jury members are also able to ask us to correct any mistakes in the information we hold on them or ask for the data to be deleted (assuming that EFA has no other obligation to keep the data; we would encourage jury members to let us use it for suppression purposes only).

Last updated on 31/01/2023